Jacobs Levy Equity Management
FDMT icon

Jacobs Levy Equity Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Jacobs Levy Equity Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-89,641
Closed -$626K – 1060
2022
Q2 		$626K Buy
+89,641
New +$871K ﹤0.01% 833
2021
Q3 		– Sell
-37,417
Closed -$901K – 1065
2021
Q2 		$901K Buy
+37,417
New +$1.15M 0.01% 757

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's FDMT Position: Q3 2022 in Review

Jacobs Levy Equity Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2022, closing a stake of 89,641 shares — an estimated $626K sold.

Jacobs Levy Equity Management first reported a position in FDMT in Q2 2021 and held it in 2 quarters. The position peaked at $901K in Q2 2021. 88 funds tracked by Wall St. Rank hold FDMT as of Q3 2022.

  • Jacobs Levy Equity Management reported no remaining 4D Molecular Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 89,641 4D Molecular Therapeutics shares in Q3 2022, an estimated $626K.
  • Jacobs Levy Equity Management first reported a position in 4D Molecular Therapeutics in Q2 2021 and held it in 2 quarters.
  • Jacobs Levy Equity Management's 4D Molecular Therapeutics position peaked at $901K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2022, filed 15 Nov 2022.